Chinese M&A back on the agenda after regulatory crackdown

China_binoculars_230px
By David Rothnie
05 Oct 2017

After a year-long barrage of regulatory intervention, Chinese corporates are re-emerging on the international deal making scene, and this time they are here to stay, writes David Rothnie.

When ChemChina announced its $44bn acquisition of Swiss pesticides group Syngenta last year, it was heralded as the arrival of Chinese conglomerates on the global M&A stage.

18 months later, and investors seem less convinced as Syngenta was forced to postpone a $7bn bond linked to the ...

Please take a trial or subscribe to access this content.

Contact our subscriptions team to discuss your access: subs@globalcapital.com

Or sign up for a trial to gain full access to the entire site for a limited period.

Free Trial

Corporate access

To discuss GlobalCapital access for your entire department or company please contact our subscriptions sales team at: subs@globalcapital.com or find out more online here.